Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpibectir and Ethionamide in Pulmonary Tuberculosis
NCT05473195Phase 2Completed
- Sponsor
- TASK Foundation
- Start
- Dec 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of alpibectir in pulmonary tuberculosis (TB) (7 arms), sponsored by TASK Foundation. Primary endpoint: Early Bactericidal Activity Colony Forming Units at 7 days. Started Dec 2022; status: completed.
02
Drugs
alpibectir
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT05473195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05473195.